Policy: STORAGE AND CONTROL OF INVESTIGATIONAL DRUGS AND DEVICES FOR CLINICAL RESEARCH

1. BACKGROUND:
Research accreditation standards of the Association for Accreditation for Human Research Protection Programs require the Health Science Center to ensure proper storage, inventory control, dispensing and tracking of investigational drugs and devices.

2. PURPOSE:
To establish policies and procedures to ensure that the handling of investigational or unlicensed test articles meets the Health Science Center standards relating to pharmacy, inventory control and documentation of investigational articles in IRB approved research protocols.

3. DEFINITIONS:
   a. Investigational drug includes any drug (approved or unapproved by the FDA) being used in research, other than the use of a marketed drug in the course of medical practice.
   b. Investigational device includes any device (approved or unapproved by the FDA) being used in research designed to evaluate safety and effectiveness of that device.

4. REFERENCES:
   b. Attachments provide sample standard operating procedures outlining responsibilities and required procedures and associated forms and logs.

5. RESPONSIBILITY:
   a. Investigators: All Investigators receiving and storing investigational drugs or investigational devices in their clinic or office areas outside of a hospital pharmacy, hospital designated service for devices, or the Investigational Drug Section of the Cancer Therapy and Research Center must:
      (1) Maintain proper environmental storage conditions with appropriate security of the items at all times.
      (2) Ensure and maintain inventory control and investigational test article accountability including ordering, receipt, inventory, and removal.
      (3) Maintain drug or device accountability documentation and reports.
      (4) Establish standard operating procedures (see attached detailed examples for handling of investigational drugs and devices).
      (5) Provide their policies and procedures for storage, control, and dispensing for review to the Assistant Vice President for Research Operations.
      (6) See 5.b and 5.d listed below as alternatives.

   b. Department Chairs: Ensure all storage areas are properly registered and approved (see 5.a and 5.c) A Division, Department, or Service may decide to designate a location and a responsible person to oversee the management of test articles to include the receipt, inventory control, dispensing accountability, and storage of these test articles for multiple investigators in a specific clinic or division/department location.
under your specified policies. The Division, Department, or Service should provide the items listed below to the Assistant Vice President for Research Operations:

(1) Identify the building, room location for the storage and management of test articles.
(2) Identify the responsible person, position title, contact number for oversight of the test articles and their contact information.
(3) Provide the specific policies and procedures for the designated clinic, service, department, or division.
(4) Provide a list of investigators currently using test articles under approved protocols in this location.

c. Assistant Vice President for Research Operations:
   (1) Review documents submitted from Investigators or HSC divisions, departments, and services and forward as appropriate for approval to:
      a) *Investigational drugs* - Director, Investigational Drug Section, Scott Soefje, Pharm D. Reviews policies and provides approval number for sites involving drugs.
      b) *Investigational devices* - Director, Office of Clinical Research, Holly Nolan, MS. Reviews policies and provides approval number for sites involving devices.

d. Investigators may also choose to no longer hold and manage study drugs at their clinics but instead use the UHS Purchasing office for Devices, UHS Pharmacy, STVHCS Pharmacy, or the CTRC Investigational Drug Section where appropriate. This office rather than the investigator or division, department, service director, is then responsible for investigational product accountability and procedures.

6. Director, Office of Clinical Research:
   a. Conduct periodic review of investigational drug and device procedures as part of the clinical study process assessment (monitoring).
   b. Provide reports to:
      (1) Director, Investigational Drug Section (re: investigational drug product accountability)
      (2) Director, Institutional Review Board
      (3) Assistant Vice President for Research Operations
      (4) Quarterly summary reports of monitoring results to Assistant Vice President for Regulatory Affairs & Compliance

[Signature]
Jenice N. Longfield, MD, MPH
Assistant Vice President for Research Operations
PURPOSE

To establish procedures for storing investigational products for Research Team/Department (RT/Dept) studies:
1. Proper storage, temperature monitoring, and access for all investigational drugs/devices maintained by the investigator.
2. Maintaining investigational drugs/device inventory and accountability.
3. Transfer of investigational drugs/devices between protocols or sites.

RESPONSIBILITY

1. The principal investigator (PI) is ultimately responsible for RT/Dept procedures for handling of investigational product and ensuring research personnel comply with these procedures. The PI provides information as required per this SOP.

2. The PI appoints an Investigational Product Manager, IPM. As per this SOP, the IPM has the following primary responsibilities:

- Maintaining and monitoring proper storage conditions
- Securing investigational products and controlling access to storage areas
- Maintain investigational drug/device inventory and accountability, including ordering and receipt
- Perform weekly inventory counts of investigational product
- Maintain accurate drug accountability reports (DAR) and device accountability logs
- Remove investigational product from inventory when orders are processed
- Quality review of all DAR and accountability logs prior to distribution to outside parties

3. The RT Coordinator conducts routine verification that procedures are being followed.
REQUIRED ITEMS FOR STORAGE AND MONITORING OF MEDICATION:

- Shelving to store room temperature medication(s) in Rooms X, Y, and Z
- Refrigerator(s) to store refrigerated medication(s): #123 and #456
- Freezer(s) to store frozen medication(s): #789
- Storage bins to separate medication inventory
- Labels to identify inventory
- Certified/calibrated NSIT thermometers for storage rooms, refrigerators, and freezers
- Temperature Monitoring Log
- Drug Accountability Record (DAR)

PROCEDURES

1. Control, Storage, and Monitoring of Investigational Product
   a. Control
      1) The area where the investigational product, i.e. drugs and devices, are stored must be a limited access area. All storage rooms have key pad access; refrigerators and freezers have combination locks.
         i. Only those employees that have delegated roles on the research team that require them to enter that area shall be allowed to do so.
         ii. The IPM is the primary individual who provides appropriate research staff any codes or keys (the PI or RT Coordinator provide back-up).
      2) Doors shall be locked at all times, whenever the IPM (or staff) is not in the area.
      3) This area should only be accessed by the IPM, approved research staff, or UTHSCSA police.

   b. Storage
      1) Store all investigational products separately, by protocol. Where appropriate use individual bins (i.e. storage containers) for each protocol. The bins should be labeled with the name of the drug/device, the sponsor, and the protocol number, and the short title of the study.
      2) Store all investigational product according to the manufacturer’s recommendations (either located in the study protocol or the package insert).
      3) The PI shall approve, prior to study start, the use of the controlled storage area for the investigational product ensuring that it will meet the temperature requirements (and any additional environmental controls) and that it has appropriate security.
c. Monitoring

1) The *IPM* monitors the temperatures of the storage areas at the beginning of each day using a Temperature Monitoring Log (*Form01_PROT002_TempLog*, see Appendix 1).
   i. This log may be divided into weekly, monthly or yearly logs. This log will be placed on the outside of the area (i.e. room, refrigerator, freezer) being monitored.
   ii. Electronic monitoring systems are used in rooms X and Z. Calibrated thermometers are used in all other areas.

2) The *IPM* reports any temperature excursions immediately to PI/Coordinators of the affected studies, manages the resolution of the problem, and documents the event.

3) The *IPM* maintains current certification to NIST* standards for all thermometers (electronic and other), to include coordinating the recalibration services. (*National Institute of Standards and Technology*)

4) The temperature logs and records shall be made available to study monitors upon request.

5) The following temperature ranges are the standards:
   i. Room temperature: 15°C to 30°C
   ii. Refrigerated temperature: 2°C to 8°C
   iii. Freezer temperature: -16°C to -30°C

6) If additional environmental considerations are required, the *IPM* must be notified.

7) The *IPM* will participate in establishing the routine procedures and documentation for monitoring the additional requirements.

8) Any storage conditions that extend beyond a single protocol should result in an update to this SOP.

2. Drug Accountability of Drugs – The *IPM* is responsible for the following:

a. Immediately recording received drugs on the Drug Accountability Record and any procedures the sponsor requires to acknowledge receipt of investigational product supply. The DAR form is included as Appendix 2 (*Form02_PROT002_DAR*).
   1) Opening and inspecting contents to verify condition upon receipt of drug shipment.
   2) Comparing invoice or packing slip to contents by lot number, dosage and quantity.
   3) Reporting any discrepancies to the sponsor immediately.

b. Maintain a separate DAR for every investigational drug.
   1) Note that open-label study drug may come in more than one dose size, requiring separate storage areas and DARs for different dosages.
2) Training staff on variable doses is important when supplies arrive.

3) Conversely, blinded or placebo-controlled drug is subject-specific and must be dispensed only to the subject to whom it has been assigned. Carefully observe assignment information on drug labels.

c. Enter the strength and/or vial size of investigational medication(s) received for an investigational study individually onto a new DAR.

   1) Verify information on the retesting dates of investigational drug. If the sponsor or manufacturer does not provide this, contact the sponsor to obtain it.

   2) Record of the retesting date and ensure no expired medications are used.

d. Log a corresponding entry in the DAR each time an investigational medication is dispensed for a specific subject.

e. Complete the DAR; explanation as follows:

   1) **Date:** date transaction occurs, i.e. date medication dispensed or date returned medication

   2) **Subject’s initials:** subject’s first and last initials

   3) **Subject’s ID No.:** subject identification number; study number; and may include study arm information for multi-arm studies

   4) **Dose:** dosage of medication dispensed and for oral medication will contain the total milligram dose

   5) **Quantity Dispensed or Received:** identifies the amount received, dispensed, returned, and wasted.

   6) **Balance Forward/Balance:** running balance

   7) **Manufacturer and Lot No.:** will include bottle number, if applicable

   8) **Re-test Date:** when the investigational product must be retested as provided by the manufacturer/sponsor

   9) **Recorder’s Initials:** the person removing, wasting, or receiving the drug supply

f. Maintain all DARs (FM 02) for the duration the study conduct.

g. Immediately dispose of partially used or empty vials after preparation or administration using hazardous waste containers as per UTHSCSA hazardous waste policies.

   1) The destruction of partially used or empty vials will not be documented in a separate entry on the DAR. Example follows:
Subject’s dose is 42.5 mg and the investigational product is provided as 10 mL vials, each with a concentration of 1 mg/mL (10 mg / 10 mL).

Five (5) vials are required to prepare this subject’s dose and 5 vials will be documented on the DAR.

Based on this SOP the 4 empty and 1 partial vials will be disposed of immediately following preparation.

No separate destruction record is necessary

Study monitors may observe the first preparation of the investigational product to verify compliance to SOP.

2) Document any investigational inventory that has to be wasted (i.e. mixing errors, broken or cored vials) will be documented on the DAR.

3) Should the sponsor require that partially filled vials are saved; they should be stored in a separate bin/location from the investigational drug supply.

4) Do not reuse partial vials, unless specifically permitted by the protocol.

h. Document returned oral medications as outlined below.

1) Upon subject’s return of oral investigational medication, document the number of tablets/capsules/etc. on the DAR as returned. Once disposed of, document as wasted on the DAR.

2) If a subject returns an empty bottle, it should not be documented in the DAR and the empty container should be placed in the biohazard waste container.

3) Due to safety concern and space limitations, it is not recommended that PIs save returned oral medications or empty returned oral medication bottles. Should a sponsor require returns to be saved, the PI must provide the special arrangements to the IPM.

i. Perform the investigational products inventory weekly. Resolve any discrepancies in a timely manner and document both the discrepancy and resolution.

j. The IPM provides the DAR(s) for each study monitor visit covering the time period between monitoring visits. The IPM should have adequate time to review the DAR to ensure the information contained in the report is accurate.

k. Upon study completion the IPM will either return remaining medication to the study sponsor or destroy on site after written approval from the study sponsor.

1) Document the return/destuction of the investigational product on the DAR.

2) Complete a final DAR (initial drug receipt through final disposal) after the inventory remaining is zero.
3) The PI and the IPM will sign original, final DAR as well as the individual(s) performing the site close out visit.

4) The IPM provides a copy to the sponsor. The original DAR(s) are provided to the RT Coordinator for retention.

3. Drug Accountability of Devices

As with investigational drugs, the investigator is ultimately responsible for the control of the device(s) under investigation. The IPM follows section 1 of this SOP, for investigational devices, and

a. The device and its packaging shall have a label with the name and place of business of the manufacturer, packer, or distributor. The device must have labeling that clearly states it is for investigational use and include any warnings/precautions (e.g. contraindications, hazards, adverse effects, interfering substances/devices).

b. Upon receipt of the study device, the shipment should be inventoried (see log at Appendix 3), verifying that the receipt date, lot number/serial or model number (sometimes date of manufacture), device type/batch number or code mark, and quantity on the packing slips match what was actually received. See the Device Accountability Log at Appendix 3.

c. Promptly bring any discrepancies to the attention of the sponsor/supplier of the device(s).

d. Retain a copy of the shipping inventory, packing slips and document inventory in the study files.

e. The devices will be stored in a secure environment according to the requirements listed in the protocol or in the investigator’s brochure. For example, the temperature or any other environmental requirements for the storage area.

f. Record daily any environmental requirements for storage. Resolve and document any discrepancies.

g. Access to the storage area will be limited to essential research personnel.

h. Each time the device is distributed it will be reported on an accountability log (see Appendix 3, FM03_PROT002_DeviceLog) containing the following information: the date the study device is dispensed/used; where it is dispensed/used; by whom it is dispensed/used; and the date and signature or initials of the person dispensing/using the study device (plus information dictated by the study protocol).

i. Record any return, repair, or destruction of the device on the accountability log (see Appendix 3).

j. Record a note of explanation why and how many device units are returned to the sponsor, repaired or otherwise disposed of; when a device is disposed of, note the identification of the person responsible.
k. Retain all accountability documents during the conduct of the study and at the conclusion of the study forward to the RT Coordinator for retention.

4. Transfers of Investigational Product
   a. Investigational Product Transfer to Satellite Sites
      i. Prior to a transfer to satellite sites, the PI must obtain written documentation of the IRB approval for the transfer and provide this to the IPM.
      ii. The PI must provide the IPM information on the satellite site’s investigational drug pharmacist and/or PI to include, name, title, complete mailing address, telephone numbers for normal business hours, and an e-mail address.
   b. Investigational Product Transfer Between Protocols:
      i. Investigational product transfer between protocols will NOT occur unless the study sponsor approves and provides documentation for transfer.
      ii. The PI must provide the IPM this documentation.
      iii. The IPM records the investigational product transfer on the DAR’s of each protocol involved.

5. Routine Verification of Compliance – The PI ensures that the RT Coordinator conducts routine verification of the procedures prescribed by this RT/Dept. The review must be documented and any discrepancies documented along with the resolution, and procedures updated as warranted. The PI reviews all verifications (signs and dates).

REFERENCES
Office of Clinical Research Policy, Storage and Control of Investigational Drugs and Devices for Clinical Research

ATTACHMENTS

1. Appendix 1 – Yearly Temperature Log - FM01_PROT002.TempLog
2. Appendix 2 – Sample Drug Accountability Record - FM02_PROT002.DAR
3. Appendix 3 – Sample Investigational Device Accountability Log – FM03_PROT002_DeviceLog
Appendix 1.
Temperature Log
Year: ____

<table>
<thead>
<tr>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>AUG</th>
<th>SEP</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Appendix 2.

**Drug Accountability Record (DAR)**

<table>
<thead>
<tr>
<th>Line#</th>
<th>Date</th>
<th>Pt initials</th>
<th>ID#</th>
<th>Dose</th>
<th>Quantity</th>
<th>Received/Dispensed</th>
<th>Balance Forward</th>
<th>Dispensing Area</th>
<th>Site Name and #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>04/29/2010</td>
<td>---</td>
<td>---</td>
<td>150 mg tabs</td>
<td>100</td>
<td>R 100</td>
<td></td>
<td>ABC, Lot 5</td>
<td>MMM</td>
</tr>
<tr>
<td>2</td>
<td>04/30/2010</td>
<td>LCK</td>
<td>01-223</td>
<td>150 mg p.o.</td>
<td>7</td>
<td>D 93</td>
<td></td>
<td>ABC, Lot 5</td>
<td>MMM</td>
</tr>
<tr>
<td>3</td>
<td>04/30/2010</td>
<td>DEF</td>
<td>01-198</td>
<td>150 mg p.o.</td>
<td>7</td>
<td>D 86</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Protocol Title:** *Randomized Trial of ABC-101 in Treatment of Women with XYZ*

**Drug Name or Number:** *ABC-101*

**Dose Form and Strength:** *Oral 150 mg*

---

**Investigator Name:** *Dr. Smith*

**IPM:** *Mary Roberts, RN*
Appendix 3.
Investigational Device Accountability Log

<table>
<thead>
<tr>
<th>DEVICE REPORT</th>
<th>DEVICE USE</th>
<th>DEVICE RETURN/REPAIR/DESTRUCTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Rec'd</td>
<td>Initials of Receiver</td>
<td>Lot No./Serial or Model No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>